Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb 5;12(4):ofaf057.
doi: 10.1093/ofid/ofaf057. eCollection 2025 Apr.

Infective Endocarditis in People Who Inject Drugs-A 5-Year Follow-up: "I've Seen the Needle and the Damage Done"

Mika Halavaara  1 , Veli-Jukka Anttila  1 , Asko Järvinen  1
Affiliations

Infective Endocarditis in People Who Inject Drugs-A 5-Year Follow-up: "I've Seen the Needle and the Damage Done"

Mika Halavaara et al. Open Forum Infect Dis. .

Abstract

Background: Infective endocarditis (IE) among people who inject drugs (PWID) has been associated with better short-term outcome. Long-term outcome of PWID with IE is poorly known.

Methods: This retrospective population-based study included PWID with IE and non-PWID adults with community-acquired IE who were diagnosed and treated in Southern Finland between 2013 and 2017 and survived the initial IE episode. All patients were followed for 5 years. Data were collected on drug use, receipt of medications for opioid use disorder (MOUD), survival, and subsequent IE episode during follow-up.

Results: Seventy-five PWID with IE and 98 patients with community-acquired IE were included. Buprenorphine and amphetamine or other stimulant were the most used substances among PWID. Sixteen PWID received MOUD before onset of IE, and 33 received MOUD at the time of discharge. Most PWID (86%) received addiction specialist consultation during the hospitalization. Fifteen patients in the PWID IE group experienced a new IE episode within 5-year follow-up as compared with 5 patients in the non-PWID IE group (odds ratio [OR], 4.65; P = .003). One-year all-cause mortality was 4.0% (3/75) in PWID IE and 4.1% (4/98) in non-PWID IE. Five-year all-cause mortality was 18.7% (14/75) in PWID IE and 13.3% (13/98) in non-PWID IE (P = .399). In multivariate analysis of the whole group, injection drug use (OR, 12.2), female gender (OR, 2.62), and higher age-adjusted comorbidity index were independent factors associated with death during 5-year follow-up.

Conclusions: Long-term survival of PWID with IE is poor, and they are at increased risk of a new IE episode as compared with non-PWID with community-acquired IE. More efforts in the treatment of addiction are needed.

Keywords: addiction treatment; endocarditis outcome; infective endocarditis; intravenous drug use; persons who inject drugs.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. A. J. has received speaker honoraria from AstraZeneca, Shionogi, and Takeda and consultation fees from AstraZeneca, GlaxoSmithKline, and Nordic Infucare. All other authors report no potential conflicts.

Figures

Graphical Abstract
Graphical Abstract
This graphical abstract is also available at Tidbit: https://tidbitapp.io/tidbits/infectious-endocarditis-in-people-who-inject-drugs-a-five-year-follow-up-c38c9e96-25b5-4cca-b7dd-83a4e5e7fc36?utm_campaign=tidbitlinkshare&utm_source=IO
Figure 1.
Figure 1.
A Kaplan-Meier survival curve showing IE-free survival, stratified by injection drug use in patients with community-acquired IE (n = 173). Abbreviations: IE, infective endocarditis; PWID, people who inject drugs.
Figure 2.
Figure 2.
The 5-year survival of patients with community-acquired IE (n = 173) stratified by injection drug use. Abbreviations: IE, infective endocarditis; PWID, people who inject drugs.
See this image and copyright information in PMC

References

    1. Rodger L, Glockler-Lauf SD, Shojaei E, et al. Clinical characteristics and factors associated with mortality in first-episode infective endocarditis among persons who inject drugs. JAMA Netw Open 2018; 1:e185220. - PMC - PubMed
    1. Rudasill SE, Sanaiha Y, Mardock AL, et al. Clinical outcomes of infective endocarditis in injection drug users. J Am Coll Cardiol 2019; 73:559–70. - PubMed
    1. Halavaara M, Martelius T, Anttila VJ, Järvinen A. Three separate clinical entities of infective endocarditis—a population-based study from Southern Finland 2013–2017. Open Forum Infect Dis 2020; 7:ofaa334. - PMC - PubMed
    1. Kadri AN, Wilner B, Hernandez AV, et al. Geographic trends, patient characteristics, and outcomes of infective endocarditis associated with drug abuse in the United States from 2002 to 2016. J Am Heart Assoc 2019; 8:e012969. - PMC - PubMed
    1. Yucel E, Bearnot B, Paras ML, et al. Diagnosis and management of infective endocarditis in people who inject drugs: JACC state-of-the-art review. J Am Coll Cardiol 2022; 79:2037–57. - PubMed